Type Whole antibody Trade names Bexxar MedlinePlus a609013 CAS ID 192391-48-3 Trade name Bexxar | Target CD20 AHFS/Drugs.com Monograph Molar mass 143,859.7 g/mol Source Mouse | |
ATC code V10XA53 (WHO) (sequential regimen with I form) | ||
Live from ash 2011 randomized phase iii trial of 131 iodine tositumomab carmustine etoposide cyta
Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, produced in mammalian cells. Combined with radioisotope iodine 131 it was called Iodine I 131 Tositumomab. Unlabelled tositumomab together with iodine-labelled tositumomab was called Bexxar and a personlized regimen using Bexxar was approved for the treatment of relapsed or chemotherapy/rituxan-refractory Non-Hodgkin lymphoma in 2003.
Contents
- Live from ash 2011 randomized phase iii trial of 131 iodine tositumomab carmustine etoposide cyta
- How to pronounce tositumomab
- References
The treatment regimen was personalized for each person receiving the drug in order to maximize the radiation delivered to the tumor and to minimize the amount of radiation to which the person would be exposed. A first dose of labelled antibody was given once, and whole-body radiation was measured with a gamma camera over seven days. Analysis of that imaging data allowed an optimal dose of labelled antibody to be calculated, which was then administered once a day, for up to seven days. Each time the labelled antibody was administered, it was always preceded by unlabelled antibody because early clinical trials had shown that total body residence times of radioactivity were longer in people who first received unlabelled antibody, so that a lower dose of labelled antibody was needed to deliver the required total dose of radiation; additionally labelled antibody targeted tumors better in people pre-treated with unlabelled antibody.
This drug combination was developed by Corixa which was purchased by GlaxoSmithKline in 2005. It was sold for about $25,000 for one round of treatment.
Sale of Bexxar was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) even though it had a 70% response rate; the lack of demand was due to the fact that oncologists could not sell it directly to patients but had to refer patients to third parties, and the emergence of other drugs that were as good and could be administered by the oncologists.